MTOR and liver cancer: Additionally, previous studies have demonstrated that SNORA23 affects liver cancer progression via the PI3K/AKT/mTOR pathway [33], while SNORA18L5 impacts the MDM2-mediated p53 pathway by influencing the binding of the ribosomal proteins L5 and L11 to MDM2 [18].